|
|
Blood, 15 June 2005, Vol. 105, No. 12, pp. 4664-4670.
Prepublished online as a Blood First Edition Paper on March 1, 2005; DOI 10.1182/blood-2005-01-0050.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation
Paula G. Heller,
Ana C. Glembotsky,
Manish J. Gandhi,
Carrie L. Cummings,
Carlos J. Pirola,
Rosana F. Marta,
Laura I. Kornblihtt,
Jonathan G. Drachman, and
Felisa C. Molinas
From the Divisions of Hematology and Molecular Cardiology, Instituto de Investigaciones Médicas Alfredo Lanari, University of Buenos Aires, Argentina; Puget Sound Blood Center, Seattle, WA; and the Division of Hematology, University of Washington, Seattle.
Germ-line heterozygous mutations in the hematopoietic transcription factor AML1 (RUNX1) have been identified in patients with familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML), which is characterized by thrombocytopenia, abnormal platelet function, and propensity to myeloid malignancies. We identified a novel mutation in the AML1 gene in an FPD/AML pedigree characterized by a single nucleotide deletion that generates a frameshift and premature chain termination (Pro218fs-Ter225). Both wild-type and mutant transcripts were expressed in affected individuals by allele-specific reverse transcriptase-polymerase chain reaction (RT-PCR). Thrombopoietin (TPO) binds to the Mpl receptor and is the major regulator of megakaryopoiesis. To explore the mechanisms underlying thrombocytopenia, we studied the TPO/Mpl pathway in this newly identified pedigree. TPO levels were mildly to moderately elevated. On flow cytometry and immunoblotting, Mpl receptor expression was decreased and TPO-induced signaling was impaired. While no mutations were identified in the MPL gene by sequence analysis, low MPL mRNA levels were found, suggesting decreased gene expression. Of particular interest, several AML1-binding motifs are present in the MPL promoter, suggesting MPL is an AML1 target. In conclusion, we identified a C-terminal AML1 mutation that leads to a decrease in Mpl receptor expression, providing a potential explanation for thrombocytopenia in this FPD/AML pedigree. (Blood. 2005;105:4664-4670)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Decreased platelet Mpl receptor in AML1 haplodeficiency: another piece of the puzzle
- A. Koneti Rao
Blood 2005 105: 4545.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
K. Kirito, K. Sakoe, D. Shinoda, Y. Takiyama, K. Kaushansky, and N. Komatsu
A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies
Haematologica,
January 1, 2008;
93(1):
155 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Savoia, C. Dufour, F. Locatelli, P. Noris, C. Ambaglio, V. Rosti, M. Zecca, S. Ferrari, F. di Bari, A. Corcione, et al.
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations
Haematologica,
September 1, 2007;
92(9):
1186 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Petit-Cocault, C. Volle-Challier, M. Fleury, B. Peault, and M. Souyri
Dual role of Mpl receptor during the establishment of definitive hematopoiesis
Development,
August 15, 2007;
134(16):
3031 - 3040.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Katsumoto, Y. Aikawa, A. Iwama, S. Ueda, H. Ichikawa, T. Ochiya, and I. Kitabayashi
MOZ is essential for maintenance of hematopoietic stem cells.
Genes & Dev.,
May 15, 2006;
20(10):
1321 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Hamelin, C. Letourneux, P.-H. Romeo, F. Porteu, and M. Gaudry
Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation
Blood,
April 15, 2006;
107(8):
3106 - 3113.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
